Janssen Announces U.S. FDA Approval Of TREMFYA™ (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis
Go back to Janssen Announces U.S. FDA Approval Of TREMFYA™ (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis| Johnson & Johnson (NYSE: JNJ) | Delayed: 239.08 +7.79 (3.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $231.29 | 52 Week High | $126.07 | |||
| Open | $235.64 | 52 Week Low | $94.28 | |||
| Day High | $239.80 | P/E | 49.70 | |||
| Day Low | $234.35 | EPS | $4.81 | |||
| Volume | 11,861,872 | |||||
